Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Trial details
- Registry ID
- NCT02968004
- Drugs studied
- MOD-4023, Somatropin
TrialRedline tracks 6 clinical trials sponsored by OPKO Health, Inc.: 2 Phase 3, 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenNCT02968004 | MOD-4023, Somatropin | Completed | 2019-08Actual |
| Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary HyperparathyroidismNCT05543928 | CTAP101 | Terminated | 2024-06-19Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric ParticipantsNCT07494045 | CTAP101 | Recruiting | 2027-10Estimated |
| Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenNCT02500316 | MOD-4023 | Completed | 2023-11Actual |
| Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19NCT04551911 | Rayaldee | Completed | 2021-10-08Actual |
| Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDINCT03602261 | Calcifediol Oral Capsule | Terminated | 2021-02-24Actual |
Names as written in the registry records.
Before: Not yet recruiting. After: Recruiting.